Newly identified autoantibodies: Relationship to idiopathic inflammatory myopathy subsets and pathogenesis

Current Opinion in Rheumatology

Volumn 20, Issue 6, 2008, Pages 675-680

  Gunawardena, Harsha ^a   Betteridge, Zoe E ^a   McHugh, Neil J ^a,b  

^a UNIVERSITY OF BATH   (United Kingdom)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

Author keywords

Cancer associated myositis; Dermatomyositis; Juvenile dermatomyositis; Myositis specific autoantibodies

Indexed keywords

ARS ANTIBODY; AUTOANTIBODY; CADM 140 ANTIBODY; EJ ANTIBODY; JO 1 ANTIBODY; KS ANTIBODY; MI 2 ANTIBODY; MJ ANTIBODY; OJ ANTIBODY; P 140 ANTIBODY; P 155 ANTIBODY; PL 12 ANTIBODY; PL 7 ANTIBODY; PMS 1 ANTIBODY; SAE ANTIBODY; SRP ANTIBODY; SUMO PROTEIN; UNCLASSIFIED DRUG; YRS ANTIBODY; ZO ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN FUNCTION; AUTOIMMUNITY; DERMATOMYOSITIS; GENETIC ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SEROTYPE;

ADULT; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; CHILD; DERMATOMYOSITIS; HUMANS; MYOSITIS; PEPTIDES; UBIQUITIN-ACTIVATING ENZYMES;

EID: 56249124622     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328313bff4     Document Type: Review

References (44)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292:344-347; 403-407.
2. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
3. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006; 8:196-203.
4. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19:523-529.
5. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93-151.
6. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.
7. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85:111-127.
8. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23:881-888.
9. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983; 304:177-179.
10. Mathews MB, Reichlin M, Hughes GR, Bernstein RM. Antithreonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984; 160:420-434.
11. Targoff IN, Arnett FC, Reichlin M. Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum 1988; 31:515-524.
12. Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986; 163:1281-1291.
13. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990; 88:241-251.
14. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992; 35:821-830.
15. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multienzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993; 91:2556-2564.
16. Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162:2315-2320.
17. Betteridge Z, Gunawardena H, North J, et al. Antisynthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007; 46:1005-1008.
18. Hashish L, Trieu EP, Sadanandan P, Targoff IN. Identification of auto-antibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome [abstract]. Arthritis Rheum 2005; 52:S312.
19. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33:1361-1370.
20. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Antisignal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635-1638.
21. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28:796-803.
22. Ghirardello A, Zampieri S, Iaccarino L, et al. Anti-Mi2 autoantibodies. Autoimmunity 2005; 38:79-83.
23. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:1571-1576.
24. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated wtth dermatomyositis. Arthritis Rheum 2006; 54:3682-3689.
25. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25-28.
26. Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56:3132-3137. Novel autoantibodies targeting small ubiquitin-like modifier enzyme, a protein involved in post-translational modification, are described in dermatomyositis.
27. Betteridge Z, Gunawardena H, Chinoy H, et al. Clinical and immunogenetic associations of anti-SAE autoantibodies in patients with dermatomyositis [abstract]. Rheumatology (Oxford) 2008; 47:S2ii85.
28. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345-1349. This study described the diagnostic utility of autoantibody testing, in particular anti-p155/140 in the prediction of CAM.
29. Gunawardena H, North J, Wedderbum LR, et al. Clinical associations of anti-p155/140 autoantibodies in adult and juvenile dermatomyositis [abstract]. Ann Rheum Dis 2007; 66:S68.
30. Gunawardena H, Wedderburn LR, North J, et al. Juvenile Dermatomyositis Research Group UK. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47:324-328. Anti-p155/140 is a major myositis-specific autoantibody in juvenile dermatomyositis and the clinical specificity is described.
31. Targoff IN, Trieu EP, Levy-Neto M, et al. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum 2006; 54:S518.
32. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997; 40:S139.
33. Targoff IN, Trieu EP, Levy-Neto M, et al. Sera with autoantibodies to the MJ antigen react with NXP2 [abstract]. Arthritis Rheum 2007; 56:S787.
34. Eloranta ML, Barbasso Helmers S, Ulfgren AK, et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007; 56:3112-3124. MSAs may play a role in disease pathogenesis. This work showed that sera positive for anti-Jo-1 and/or anti-Ro52/Ro60 can induce IFN production by peripheral blood mononuclear cells in vitro. Markers of IFN production were increased in myositis muscle.
35. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601.
36. Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum 2007; 56:2729-2739. Novel conformation of histidyl-tRNA synthetase generated by granzyme-B induced cleavage is enriched in the lung providing further emphasis on autoantigen expression in initiating micro-environments shaping disease expression.
37. Wang HB, Zhang Y. Mi2, an autoantigen for dermatomyositis, is an ATP-dependant nucleosome remodelling factor. Nucleic Acid Res 2001; 29:2517-2521.
38. Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 2007; 134:1571-1582. Using a conditional gene targeting mouse model, a critical role of Mi-2 was elucidated showing that this nuclear protein is required for development of the basal epidermis.
39. Dohmen RJ. SUMO protein modification. Biochim Biophys Acta 2004; 1695:113-131.
40. Gong Z, Brackertz M, Renkawitz R. SUMO modification enhances p66-mediated transcriptional repression of the Mi-2/NuRD complex. Mol Cell Biol 2006; 26:4519-4528.
41. Kimura Y, Sakai F, Nakano O, et al. The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem 2002; 277:20611-20617.
42. Rosendorff A, Sakakibara S, Lu S, et al. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci USA 2006; 103:5308-5313.
43. Yan KP, Dolle P, Mark M, et al. Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene. Gene 2004; 334:3-13.
44. Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008; 4:201-209. This review highlights how autoantigens are clues to the pathogenesis of myositis and CAM.